70% of 350 US physicians will increase the use niacin for patients, says report

Sermo (http://www.sermo.com), the world's largest online physician's community, today announced the results of a new report indicating that 70% of 350 US physician respondents would increase their use of niacin based on results from the ARBITER 6-HALTS trial. The head-to-head trial demonstrated the superiority of extended-release niacin (Abbott) over ezetimibe (Merck’s Zetia) when combined with statin therapy. This data is part of Sermo’s new FirstLine report series, which rapidly assess physician reaction to major events impacting the US pharmaceutical market.

According to the report, 70% of physicians would increase their use of niacin for patients in which monotherapy statin usage was not sufficient. One physician comment captured much of the discussion: “It will change my practice in that it reminds me to try niacin more often, even though it requires more hand-holding with patients and slow titration.”

This report also indicates that almost half of respondents were unable to rate carotid intima-media thickness (CIMT) as being particularly good or bad as a surrogate marker for clinical end points. Less than 40% rate CIMT as being particularly good and cardiologists were the least likely to consider CIMT as being a particularly strong surrogate marker.

“There is still uncertainty in the physician community on two key factors. The first is whether or not physicians feel that carotid intima-media thickness is a good enough surrogate for clinical end points -- physicians interviewed were largely unsure,” said Sermo Inc. analyst, Richard Leigh-Pemberton, MD. “Second, while over half were unsure, one quarter of respondents believe that the paradoxical progression of atherosclerosis seen with larger reductions of LDL in the ezetimibe group was a real (i.e., biologically plausible) finding.”

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Alirocumab reduces dangerous coronary plaque and stabilizes high-risk lesions